|Description:||Rabbit polyclonal antibody to APOA5.|
|Immunogen:||Recombinant protein of human APOA5|
|Formulation:||PBS with 0.02% sodium azide, 50% glycerol, pH7.3.|
|Background:||Apolipoprotein A5 (ApoA5) is fast gaining attention as a key regulator of serum triglyceride concentrations. An ApoA5 mouse knock-out model produced an approximately four fold increase in serum triglycerides, whereas a knock-in model with human ApoA5 produced 50–70% lower concentrations of mouse serum triglycerides. In addition, peroxisome proliferator-activated receptor- agonists, which are used clinically to lower serum triglyceride concentrations, cause increased ApoA5 mRNA expression. Despite these compelling molecular biology data, relatively little is known about ApoA5 protein in human serum.This antibody pair detected recombinant apoa5 protein in sandwich ELISA format and could be potential reagents for the development of clinical diagnostic kits.|
|Storage:||Store at -20℃. Avoid freeze / thaw cycles.|
|Recommended Dilutions:||WB 1:500 - 1:2000, IHC 1:50 - 1:100|
Target (Information from UniProt)
|Function:||Minor apolipoprotein mainly associated with HDL and to a lesser extent with VLDL. May also be associated with chylomicrons. Important determinant of plasma triglyceride (TG) levels by both being a potent stimulator of apo-CII lipoprotein lipase (LPL) TG hydrolysis and a inhibitor of the hepatic VLDL-TG production rate (without affecting the VLDL-apoB production rate) (By similarity). Activates poorly lecithin:cholesterol acyltransferase (LCAT) and does not enhance efflux of cholesterol from macrophages.|
|Tissue Specificity:||Liver and plasma.|
|Involvement in Disease:||Hypertriglyceridemia, familial: A common inherited disorder in which the concentration of very low density lipoprotein (VLDL) is elevated in the plasma. This leads to increased risk of heart disease, obesity, and pancreatitis.
Hyperlipoproteinemia 5: Characterized by increased amounts of chylomicrons and very low density lipoprotein (VLDL) and decreased low density lipoprotein (LDL) and high density lipoprotein (HDL) in the plasma after a fast. Numerous conditions cause this phenotype, including insulin-dependent diabetes mellitus, contraceptive steroids, alcohol abuse, and glycogen storage disease type 1A (GSD1A).
|Sequence Similarities:||Belongs to the apolipoprotein A1/A4/E family.|
|Post-Translational Modification:||Phosphorylated by FAM20C in the extracellular medium.|
Western blot analysis of extracts of Recombinant protein, using APOA5 antibody.
Immunohistochemistry of paraffin-embedded human liver using APOA5 antibody at dilution of 1:100 (40x lens).